RemeGen Co., Ltd. (OTCMKTS:REGMF) Sees Large Decline in Short Interest

RemeGen Co., Ltd. (OTCMKTS:REGMF) saw a large drop in short interest in June. As of June 30th, there was short interest totaling 554,532 shares, a drop of 53.0% from the June 15th total of 1,180,532 shares. Based on an average daily volume of 0 shares, the short-interest ratio is currently ∞ days.

RemeGen Price Performance

Shares of REGMF opened at $9.50 on Thursday. RemeGen has a 52-week low of $9.50 and a 52-week high of $15.91. The firm’s fifty day moving average is $10.57 and its two-hundred day moving average is $10.41.

RemeGen Company Profile

RemeGen Co, Ltd. is a Shanghai-based biopharmaceutical company focused on the research, development and commercialization of innovative antibody-based therapeutics for oncology and immunology. Since its founding in 2009, RemeGen has built a portfolio of antibody–drug conjugates (ADCs), monoclonal antibodies and bispecific antibodies aimed at addressing a range of solid tumors and immune-related conditions. The company leverages its in-house discovery, engineering and manufacturing capabilities to advance its pipeline from preclinical stages through clinical trials.

RemeGen’s lead product candidate, Disitamab Vedotin (RC48), is a HER2-targeting ADC that has received regulatory approval in China for HER2-positive gastric cancer and urothelial carcinoma.